An official website of the United States government
Home
Name
Voranigo
Alternate Names
Vorasidenib
Abbreviations
None
Category
Chemotherapy
Subcategory
IDH2 inhibitor
NSC Number
None
Primary Site
CNS
Histology
Astrocytoma; oligodendroglioma
Remarks
August 6, 2024 The FDA approved vorasidenib (Voranigo), an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor, for adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation, following surgery including biopsy, sub-total resection, or gross total resection.
Coding
This drug should be coded
